Setmelanotide

Mechanism

An FDA-approved injection for rare genetic obesity caused by specific gene mutations (POMC, PCSK1, LEPR deficiency). It works by activating the MC4R receptor in the brain that controls hunger and metabolism — the same receptor affected by PT-141 and MT-2, but this one is specifically designed for appetite regulation. Not for general weight loss.

Effects

## Setmelanotide (Imcivree) — System-by-System Effects ### Metabolic/Appetite System (Primary) - **MC4R agonism**: Setmelanotide is a selective melanocortin-4 receptor (MC4R) agonist. MC4R is the key receptor in the hypothalamic melanocortin pathway that controls satiety and energy expenditure. [Tier 1] - **Appetite reduction**: Restores satiety signaling in patients with genetic defects upstream of MC4R. Patients experience normalized hunger for the first time in their lives. [Tier 1 — pivotal trial data] - **Weight loss**: In pivotal trials, patients with POMC, PCSK1, or LEPR deficiency obesity lost 25-51% of body weight (mean ~25% BMI reduction). These are extraordinary results in a population that was previously treatment-resistant. [Tier 1] - **Energy expenditure**: MC4R agonism may also increase energy expenditure, contributing to weight loss beyond appetite effects. [Tier 2] ### Endocrine System - **Melanocortin pathway**: Setmelanotide activates MC4R, bypassing upstream defects in POMC (pro-opiomelanocortin), PCSK1 (proprotein convertase), or LEPR (leptin receptor) pathways. This is a precision medicine approach — treating the specific molecular defect. [Tier 1] - **Leptin-melanocortin axis**: In normal physiology, leptin → POMC neurons → α-MSH → MC4R → satiety. Genetic defects at any point break this cascade. Setmelanotide restores signaling at the MC4R level. [Tier 1] - **Adrenal function**: MC4R is related to other melanocortin receptors (MC1R-MC5R). Selectivity for MC4R minimizes effects on adrenal function (MC2R) and pigmentation (MC1R), though some cross-reactivity occurs. [Tier 1] ### Dermatological - **Skin hyperpigmentation**: The most common side effect. Setmelanotide has some activity at MC1R, which regulates melanin production. Patients develop diffuse skin darkening. This is generally mild and cosmetically manageable but notable. [Tier 1 — clinical trial data] ### Sexual Function - **Penile erection**: MC4R agonism can cause spontaneous erections. This was a side effect noted with earlier melanocortin agonists (PT-141/bremelanotide was developed from this observation). Occurs in some male patients. [Tier 1]

Practitioner Guide

## Setmelanotide (Imcivree) — Practitioner Guide ### Clinical Profile Setmelanotide is an FDA-approved MC4R agonist for severe obesity due to specific genetic defects: POMC deficiency, PCSK1 deficiency, or LEPR deficiency. It is a landmark precision medicine therapy — the first approved drug targeting a specific genetic cause of obesity. ### Approved Indications (FDA, 2020) - Chronic weight management in patients aged ≥6 years with obesity due to: - POMC deficiency (homozygous or compound heterozygous loss-of-function variants) - PCSK1 deficiency - LEPR deficiency (added 2022) - Confirmed by genetic testing showing variants considered pathogenic, likely pathogenic, or of uncertain significance ### Dosing - **Initiation**: 2mg SC daily for 2 weeks - **Titration**: Increase to 3mg SC daily if tolerated - **Assessment**: If ≥5% weight loss is not achieved in 12-16 weeks at 3mg, consider discontinuation (genetic re-evaluation may be warranted) - **Administration**: Once-daily subcutaneous injection, rotating injection sites ### Genetic Testing Requirement - **Mandatory**: Setmelanotide requires confirmation of qualifying genetic mutations before prescribing - **Panel testing**: Obesity gene panels including POMC, PCSK1, LEPR, and related genes are commercially available - **Who to test**: Patients with severe, early-onset obesity (typically before age 5), hyperphagia out of proportion to social/behavioral factors, family history suggestive of monogenic obesity - **Prevalence**: These genetic forms are rare (estimated <1:1,000 of all obesity). However, they are likely underdiagnosed. ### Common Side Effects - **Skin hyperpigmentation** (75%+): Diffuse darkening of skin. Generally mild-moderate. Related to MC1R activity. - **Injection site reactions** (45%): Pain, erythema, pruritis at injection site. - **Spontaneous penile erection** (in males): MC4R-mediated. Usually mild and transient. - **Nausea/diarrhea**: GI symptoms in some patients. - **Depression/suicidal ideation**: Black box warning. Monitor mood, especially in adolescents. May relate to MC4R's role in mood regulation. ### Important Clinical Considerations - **This is NOT for common obesity**: Setmelanotide does not work for polygenic/lifestyle obesity. It specifically treats upstream melanocortin pathway defects. - **Think of it when you see**: Severe obesity starting in infancy/early childhood, insatiable hunger (true hyperphagia, not emotional eating), red hair or pale skin (POMC deficiency can cause this), adrenal insufficiency (POMC deficiency) - **Life-changing for the right patient**: Patients with these genetic forms of obesity often have extreme hyperphagia — literally uncontrollable hunger since birth. Setmelanotide can normalize their hunger. Families describe it as miraculous. - **Specialty prescribing**: Should be managed by endocrinologists or obesity medicine specialists familiar with genetic obesity. REMS-like monitoring is appropriate. ### Comparison with Other MC4R-Related Agents - **PT-141 (Bremelanotide)**: Non-selective melanocortin agonist approved for HSDD (sexual dysfunction). Different indication, less MC4R selectivity. - **Melanotan II**: Research peptide, non-selective melanocortin agonist. Used off-label for tanning and sexual function. NOT interchangeable with setmelanotide. Safety profile is worse. - **Setmelanotide advantage**: Highest selectivity for MC4R with least MC1R/MC3R/MC5R cross-reactivity among available melanocortin agonists.

Dosing Protocols

Contraindications & Cautions

• hard stop — Melanoma or history of melanoma
  Setmelanotide activates MC4R and has some MC1R activity. Melanocortin receptor activation stimulates melanocyte activity and could theoretically promote melanoma development, growth, or recurrence.
  Action: Do not use in patients with active melanoma or history of melanoma.
• hard stop — Pregnancy
  Weight loss during pregnancy is not indicated and may cause fetal harm. Setmelanotide is contraindicated during pregnancy per IMCIVREE prescribing information.
  Action: Discontinue if pregnancy is detected. Do not initiate during pregnancy. Advise contraception.
• hard stop — Breastfeeding
  Insufficient data on excretion in breast milk. Weight loss during breastfeeding may affect milk production.
  Action: Do not use while breastfeeding.
• hard stop — Under 18 years of age
  FDA-approved only for specific genetic conditions under specialist care. Not for general pediatric use.
  Action: Do not provide outside specialist metabolic/genetic care.
• monitor — Depression or suicidal ideation
  Suicidal ideation and depression have been reported in clinical trials of setmelanotide. Labeled warning per IMCIVREE prescribing information.
  Action: Monitor mood and mental health closely. Ensure mental health support is available. Discontinue and seek emergency care if suicidal ideation develops.
• caution — Obesity without confirmed genetic etiology
  Setmelanotide (IMCIVREE) is FDA-approved ONLY for obesity due to specific genetic mutations (POMC, PCSK1, LEPR deficiency, Bardet-Biedl syndrome). It has not demonstrated efficacy in general obesity and should not be used off-label for this purpose.
  Action: Confirm genetic testing results before use. Not indicated for general or polygenic obesity.

Evidence

• MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency

  Clement K, Biebermann H, Farooqi IS, Van der Ploeg L, Wolber B, Grattan DR, Kuhnen P, Mahmood A, Oelkrug R, Krude H, Wiegand S (2018) — Nature Medicine — PMID: 30275570

  Setmelanotide (MC4R agonist) produced dramatic and sustained weight loss in patients with biallelic leptin receptor (LEPR) deficiency — a severe genetic obesity disorder unresponsive to other treatments. Patients lost ~12% body weight with significant hunger reduction over 1 year. First targeted therapy for monogenic obesity. Led to FDA approval (Imcivree) for POMC, PCSK1, and LEPR deficiency obesity.

  strong

• Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist

  Kuhnen P, Clement K, Wiegand S, Blankenstein O, Gottesdiener K, Martini LL, Mai K, Blume-Peytavi U, Gruters A, Krude H (2016) — New England Journal of Medicine — PMID: 27626518

  Two patients with POMC deficiency and severe childhood-onset obesity experienced dramatic weight loss (51 kg over 42 weeks in one patient) with setmelanotide treatment. Hunger scores normalized and hyperphagia resolved. Demonstrated proof-of-concept for targeted MC4R agonism downstream of the leptin-melanocortin pathway defect.

  moderate

Research Summary

## Setmelanotide (Imcivree) — Research Summary ### Tier 1 (Strong Clinical Evidence) - **FDA approval (2020)**: Based on pivotal Phase 3 studies in POMC and PCSK1 deficiency obesity. Extended to LEPR deficiency (2022). - **Pivotal trials**: Open-label studies showed ≥10% weight loss in 80% of POMC deficiency patients and 45% of LEPR deficiency patients. Mean BMI reduction ~25%. - **Mechanism**: MC4R agonism is well-characterized. The melanocortin pathway in appetite regulation is supported by decades of research. - **Safety**: Well-characterized safety profile from clinical trials. Black box warning for depression/suicidal ideation. - **Genetic specificity**: Validated approach of treating specific genetic defects with targeted pharmacology. ### Tier 2 (Moderate Evidence) - **Additional genetic forms**: Ongoing studies evaluating setmelanotide in other genetic obesities (Bardet-Biedl syndrome, Alstrom syndrome, SH2B1 deficiency, MC4R heterozygous mutations). - **Bardet-Biedl syndrome**: Phase 3 trial showed significant weight loss, leading to expanded indication consideration. - **Long-term data**: Open-label extensions show sustained weight loss over 2+ years. ### Tier 3 (Emerging) - **Broader obesity application**: Whether MC4R agonism could benefit a wider population with partial melanocortin pathway dysfunction (not classic monogenic obesity) is being explored. - **Combination strategies**: Potential combination with GLP-1 agonists for additive appetite suppression in genetic obesity. ### Key Research Gaps - Long-term (5+ year) safety and efficacy data - Identification of additional genetic forms that respond to MC4R agonism - Whether partial MC4R agonism could benefit common obesity - Mood effects need better characterization